175140-00-8

Basic information

• Product Name: CP 376395
• Synonyms: CP 376395;CP 376395 hydrochloride;N-(1-Ethylpropyl)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-4-pyridinaminehydrochloride
• CAS NO: 175140-00-8
• Molecular Formula: C21H30N2O.ClH
• Molecular Weight: 362.942
• Mol File: 175140-00-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Desiccate at RT
• CAS DataBase Reference: CP 376395(CAS DataBase Reference)
• NIST Chemistry Reference: CP 376395(175140-00-8)
• EPA Substance Registry System: CP 376395(175140-00-8)

Safety Data

• Hazardous Substances Data: 175140-00-8(Hazardous Substances Data)

Usage

Biological Activity

Potent and selective CRF 1 receptor antagonist (K i values are 12 and >10000 nM for CRF 1 and CRF 2 receptors respectively). Attenuates CRF-induced activation of the HPA axis in vivo following i.v. administration. Orally active.

Upstream product

• 190771-02-9 4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester 

Relevant articles and documents

2-Aryloxy-4-alkylaminopyridines: Discovery of novel corticotropin-releasing factor 1 antagonists

An orally active clinical candidate of corticotropin-releasing factor 1 (CRF1) antagonist 1 showed a significant positive food effect in dog and human after oral administration. Efforts to address the food effect issue led us to explore and dis

Corticotropin releasing factor antagonists

Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo

Use of CRF antagonists and renin-angiotensin system inhibitors

The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.

QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death

A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.

New uses for corticotropin releasing factor antagonists

A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.

Method of treating heart failure

This invention relates to method for treating a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dime

Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure

This invention relates to treatments for a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dimethyl-

CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou